Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study

Autor: James Welker, Juan D Pulido, Andrew T Catanzaro, Carlos D Malvestutto, Zihai Li, Jonathan B Cohen, Eric D Whitman, Dana Byrne, Olivia K Giddings, Jordan E Lake, Joel V Chua, Ella Li, Jian Chen, Xiang Zhou, Kun He, Davis Gates, Amarjot Kaur, Jamie Chen, Hung-Yen Chou, Martin Devenport, Raymond Touomou, Shyamasundaran Kottilil, Yang Liu, Pan Zheng, Jai Thakor, Imaan Khan, Nicole Do, Josephine Faragalla, Andrea Hook, Sarah Kern, Janira V. Ramos, Jason Ward, John Higson, Meena Dam, Dawn Serkin, Pooja Karloopia, Wendy Moore, Mark Scofield, David Jeffery Childers, Jeffrey S. Cantrell, Millie Corgan, Jing Liu, Denise Redvers-Higgins, Hua Han, Jiyun Hou, Yudi Pan, Karyn Tucker, Xiaoyan Zhang, Joel V. Chua, Jennifer Husson, Shivakumar Narayanan, Jaqueline Bran, Ka Wing Joyce Lam, Alicia Jeffrey, Olivia K. Giddings, Jennie Pexa, Mario Becerra, Kathleen W. Gray, Nicole Richmond, Chukwuemeka Nzelibe, Carlos D. Malvestutto, Susan Koletar, Mahdee Sobhanie, Jan Clark, Kelsi Reynolds, Karthik Chakravarthy, Kevin Weller, Mohamed Yusuf, Jennifer Severing, Kelley Barley, Juan D. Pulido, Jennifer C. Fulton, William Gil, M.D. Jeanine, Richmond R.N., Sandy Jones, Kristina Clemmer, Lisa Pedroza, Emily Nicole Davidson, Amanda Logan, Katie Grant, Eric D. Whitman, Jason Kessler, Robert Roland, Rosemary Stefiniw, Molly Maurer, Salome Geene, Christopher F. Buck, Debra Connolly, Patrice Light, Sunanda Baviskar, Yee Won Low, Kyra Michalski, Pamela Giordano, Jennifer Chao, Michelle Williams, Amulya Makkapati, Andrew T. Catanzaro, Jonathan B. Cohen, Mehad Musbah, Pramila Jaladanki, Ying Yuan, Shilpa Rele, Desirae Stewart, Starlet Lewis, Ian Sankar, Nabulungi Kasumba, Kaylia Biney, Elham Hekmat, Jordan E. Lake, Bindu Akkanti, Melissa J. Reimer-McAtee, Marisel Negret Hernandez

Publikováno v: The Lancet. Infectious diseases. 22(5)

Non-antiviral therapeutic options are required for the treatment of hospitalised patients with COVID-19. CD24Fc is an immunomodulator with potential to reduce the exaggerated inflammatory response to tissue injuries. We aimed to evaluate the safety a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6942fc252d729f16df5ccd60b55adb2f
https://pubmed.ncbi.nlm.nih.gov/35286842